The Evolving Treatment Landscape and Value-Based Considerations for the Management of Wet Age-Related Macular Degeneration and Diabetic Macular Edema

Jim Kenney, RPh, MBA, opens a discussion surrounding wet age-related macular degeneration (AMD) and diabetic macular edema (DME).

Joseph Coney, MD, FASRS, FACS, discusses the difference between population groups in age-related macular degeneration (AMD) and diabetic macular edema (DME)

Dr Coney and Veeral Sheth, MD, MBA, FACS, FASRS, discuss treatment selection, treatment goals, and unmet needs for patients diagnosed with wet AMD and DME.

Dr Sheth discusses his insights on anti-VEGF therapy that he has noticed in the treatment of wet AMD over the last decade, and Caesar Luo, MD, FASRS, FACS shares his insight on new treatment options and their impact on patient access and cost considerations.

Dr Coney discusses the variability of frequency dosing with anti-VEGF therapy in patients with wet AMD and DME, and Dr Sheth expands on Ang-2 and its contribution to the development of vascular instability in wet AMD.

Key opinion leaders discuss faricimab, its impact on the treatment landscape for wet AMD/DME, and what payers should look for when considering formulary positioning or utilization-management strategies.

Dr Coney expands on the role and impact of approved label dosing of faricimab.

Veeral Sheth, MD, MBA, FACS discusses re-treatment in patients with wet AMD who have previously failed an anti-VEGF therapy.

Drs Coney, Luo, and Sheth discuss potential novel treatment mechanisms or options that we could see in the future with wet AMD and DME.

A panel of medical experts discuss diagnostic imaging surrounding DME and wet AMD.

Caesar Luo, MD, FASRS, FACS discusses the biggest barriers for patients with wet AMD and DME to receiving optimal treatment and his strategies to overcome these barriers.

Veeral Sheth, MD, MBA, FACS, Joseph Coney, MD, FASRS, FACS, and Caesar Luo, MD, FASRS, FACS discuss their experience with utilization management strategies.

Joseph Coney, MD, FASRS, FACS, discusses switching anti-VEGF agents in the treatment of wet AMD and what payers should consider when switching anti-VEGF therapies.

Dr Sheth discusses the evolution of access to treatment for AMD/DME over the past few years and initiatives to expand treatment access.

The panelists discuss how payers can best engage with the retinal disease community on a provider and patient level.

In their closing thoughts, the expert panelists discuss the future of the disease state and treatment options, and how they expect provider, patient, and payer value perception to change in the future.